Get the Stockscreener App
73.49
2.07%
1.49
After Hours:
73.49
Inhibrx Biosciences Inc stock is traded at $73.49, with a volume of 146.79K.
It is up +2.07% in the last 24 hours and down -8.38% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$72.00
Open:
$72
24h Volume:
146.79K
Relative Volume:
0.38
Market Cap:
$1.07B
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.6193
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
+0.81%
1M Performance:
-8.38%
6M Performance:
+218.41%
1Y Performance:
+492.18%
1-Day Range:
$71.62
$74.00
1-Week Range:
$71.25
$82.16
52-Week Range:
$10.80
$94.56
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
73.49 | 1.05B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN
S P Trends: Whats the outlook for SAIAs sectorDay Trade & High Accuracy Trade Alerts - baoquankhu1.vn
Aug Highlights: Is BILI benefiting from interest rate changesDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Sell Signal: Is Gorilla Technology Group Inc trading at a discountJuly 2025 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Fed Watch: Will Hennessy Advisors Inc stock hit new highs in YEARLong Setup & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Responsive Playbooks and the INBX Inflection - Stock Traders Daily
Short Interest in Inhibrx Biosciences, Inc. (NASDAQ:INBX) Rises By 63.1% - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Nasdaq Futures Science-Driven Path - Kalkine Media
Risk Hedge: Whats the beta of Inhibrx Biosciences Inc stockEarnings Miss & Fast Gain Swing Alerts - baoquankhu1.vn
Earnings Risk: Is Inhibrx Biosciences Inc stock a smart buy before Fed meetingJuly 2025 Highlights & Low Risk Profit Maximizing Plans - Bộ Nội Vụ
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.5%What's Next? - MarketBeat
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too (INBX) - Seeking Alpha
Is Inhibrx Biosciences Inc. stock attractive for passive investorsJuly 2025 Big Picture & Low Risk High Reward Trade Ideas - Улправда
Is Inhibrx Biosciences Inc. stock dividend yield sustainable2025 Biggest Moves & High Conviction Trade Alerts - Улправда
Can Inhibrx Biosciences Inc. stock deliver surprise earnings beatTake Profit & AI Powered Buy and Sell Recommendations - Улправда
Understanding the Setup: (INBX) and Scalable Risk - Stock Traders Daily
What drives Inhibrx Biosciences Inc stock priceEarnings Per Share Trends & Missed Nvidia? Don’t Miss This One - Early Times
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Sees Large Decline in Short Interest - MarketBeat
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts - Insider Monkey
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 7.2% – Here’s Why - Defense World
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 7.2%Should You Buy? - MarketBeat
Why Inhibrx's Recent Strength May Not Be Built to LastInhibrx Biosciences (NASDAQ:INBX) - Benzinga
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 7.9%Here's Why - MarketBeat
Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - 富途牛牛
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 1-Year HighHere's Why - MarketBeat
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Why Inhibrx Biosciences Inc. stock could rally in 2025July 2025 Market Mood & Fast Gain Stock Tips - Улправда
Is Inhibrx Biosciences Inc. stock trading at a premium valuation2025 Dividend Review & Low Risk Investment Opportunities - bolumsonucanavari.com
Buyout Rumor: How Inhibrx Biosciences Inc. stock benefits from tech adoptionWall Street Watch & High Yield Equity Trading Tips - ulpravda.ru
Can Inhibrx Biosciences Inc. stock withstand economic slowdownWeekly Trend Recap & Short-Term Trading Alerts - DonanımHaber
How Inhibrx Biosciences Inc. stock benefits from tech adoptionJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Will Inhibrx Biosciences Inc. stock deliver consistent dividends2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates - Yahoo Finance
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates - simplywall.st
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - The Malaysian Reserve
Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures - Investing.com Canada
Inhibrx Biosciences, Inc provides progress updates on the Inbrx-106 program and the expansion cohorts of the Ozekibart (Inbrx-109) program - marketscreener.com
Inhibrx Biosciences Announced An Update On The INBRX-106 Phase 2/3 Clinical Trial In Combination With Keytruda; Inhibrx Expects To Complete Enrollment In The Phase 2 Portion Of The Trial During The First Quarter Of 2026 - Sahm
Inhibrx Biosciences Provides Updates on Clinical Trials - TradingView — Track All Markets
[8-K] Inhibrx Biosciences, Inc. Reports Material Event | INBX SEC FilingForm 8-K - Stock Titan
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 6.6%Here's Why - MarketBeat
Inhibrx provides updates on cancer treatment clinical trials - Investing.com
Inhibrx Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
EDGAR Filing Documents for 0002007919-25-000093 - SEC.gov
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX - MarketBeat
Why Is INBX Stock Rising Today? - MSN
Franklin Resources Inc. Makes New $316,000 Investment in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences advances sarcoma research with ozekibart trial results - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5%Here's What Happened - MarketBeat
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):